Sale!

Comprehensive Hereditary Cancer Panel 154 Genes Test

Original price was: 9,600 د.إ.Current price is: 7,200 د.إ.

-25%

The Comprehensive Hereditary Cancer Panel 154 Genes Test, available at DNA Labs UAE for 7200 AED, is a state-of-the-art genetic screening designed to assess an individual’s risk for various hereditary cancers. This extensive test analyzes 154 genes known to be associated with an increased risk of developing cancer, including but not limited to breast, ovarian, colorectal, and pancreatic cancers. By examining a person’s DNA, the test identifies specific mutations that could signify a higher likelihood of cancer, enabling early detection and proactive management strategies. The results from this panel can provide valuable information for both the individual tested and their family members, as certain genetic mutations may be inherited. Conducted in the advanced facilities of DNA Labs UAE, this test is a powerful tool in the ongoing fight against cancer, offering individuals insights into their genetic makeup and helping them make informed decisions about their health and preventive care.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Comprehensive Hereditary Cancer Panel 154 genes Test

Test Name: Comprehensive Hereditary Cancer Panel 154 genes Test

Components: EDTA Vacutainer (2ml)

Price: 7200.0 AED

Sample Condition: Peripheral Blood

Report Delivery: 4-6 weeks

Method: NGS (Next-Generation Sequencing)

Test Type: Genetics

Doctor: General Physician

Test Department: Pre Test Information

Comprehensive Hereditary Cancer Panel (154 genes) can be done with a doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

The Comprehensive Hereditary Cancer Panel (154 genes) is a genetic test that analyzes a person’s DNA for mutations or changes in 154 genes associated with an increased risk of developing hereditary cancers. These genes are involved in various biological pathways, including DNA repair, cell growth and division, and tumor suppression.

The panel includes genes associated with a wide range of cancers, including breast, ovarian, colorectal, pancreatic, prostate, and melanoma. The test can help identify individuals who may have an increased risk of developing cancer and provide information that can guide personalized screening and prevention strategies.

The test is typically recommended for individuals with a personal or family history of cancer, particularly those with a known or suspected hereditary cancer syndrome. It may also be recommended for individuals who have been diagnosed with cancer at a young age or have multiple primary cancers.

The test involves a blood or saliva sample, which is analyzed using next-generation sequencing technology. Results are typically available within a few weeks and are interpreted by a genetic counselor or healthcare provider trained in genetics.

It is important to note that a positive result on the panel does not necessarily mean that an individual will develop cancer, but it does indicate an increased risk. Additional screening and prevention measures may be recommended based on the individual’s specific genetic findings and personal and family history of cancer.

Test Name Comprehensive Hereditary Cancer Panel 154 genes Test
Components EDTA Vacutainer (2ml)
Price 7200.0 AED
Sample Condition Peripheral Blood
Report Delivery 4-6 weeks
Method NGS
Test type Genetics
Doctor General Physician
Test Department:
Pre Test Information Comprehensive Hereditary Cancer Panel (154 genes) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

The Comprehensive Hereditary Cancer Panel (154 genes) is a genetic test that analyzes a person’s DNA for mutations or changes in 154 genes associated with an increased risk of developing hereditary cancers. These genes are involved in various biological pathways, including DNA repair, cell growth and division, and tumor suppression.

The panel includes genes associated with a wide range of cancers, including breast, ovarian, colorectal, pancreatic, prostate, and melanoma. The test can help identify individuals who may have an increased risk of developing cancer and provide information that can guide personalized screening and prevention strategies.

The test is typically recommended for individuals with a personal or family history of cancer, particularly those with a known or suspected hereditary cancer syndrome. It may also be recommended for individuals who have been diagnosed with cancer at a young age or have multiple primary cancers.

The test involves a blood or saliva sample, which is analyzed using next-generation sequencing technology. Results are typically available within a few weeks and are interpreted by a genetic counselor or healthcare provider trained in genetics.

It is important to note that a positive result on the panel does not necessarily mean that an individual will develop cancer, but it does indicate an increased risk. Additional screening and prevention measures may be recommended based on the individual’s specific genetic findings and personal and family history of cancer.